OncoCyte Corporation
OCX
$3.44
$0.051.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 373.25% | -73.19% | -77.54% | -40.74% | 14.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 373.25% | -73.19% | -77.54% | -40.74% | 14.60% |
| Cost of Revenue | 112.47% | -72.96% | -81.07% | -4.91% | 47.12% |
| Gross Profit | 749.47% | -73.33% | -75.51% | -337.50% | -2,275.00% |
| SG&A Expenses | 57.30% | 13.35% | -15.43% | -14.32% | -48.28% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | -4.35% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.61% | 16.81% | -8.78% | -8.57% | -14.47% |
| Operating Income | -7.22% | -24.34% | 3.35% | 7.04% | 15.80% |
| Income Before Tax | -109.55% | -107.94% | 45.64% | -253.20% | -33.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -109.55% | -107.94% | 45.64% | -253.20% | -33.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.55% | -107.94% | 45.64% | -400.99% | 64.44% |
| EBIT | -7.22% | -24.34% | 3.35% | 7.04% | 15.80% |
| EBITDA | -2.68% | -28.38% | 1.20% | 5.23% | -0.08% |
| EPS Basic | 1.60% | -21.47% | 66.64% | -441.06% | 74.27% |
| Normalized Basic EPS | 47.45% | 23.74% | 40.48% | 34.70% | 46.03% |
| EPS Diluted | 1.60% | -21.47% | 66.64% | -441.49% | 74.27% |
| Normalized Diluted EPS | 47.45% | 23.74% | 40.48% | 34.64% | 46.03% |
| Average Basic Shares Outstanding | 110.28% | 66.11% | 59.09% | 38.70% | 39.25% |
| Average Diluted Shares Outstanding | 110.28% | 66.11% | 59.09% | 38.59% | 39.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |